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Introduction
Cerebral microbleeds (CMBs) are tiny perivascular hemor-
rhages characterized by the presence of hemosiderin-laden 
macrophages close to disrupted cerebral small vessels, which 
appear as small and rounded lesions of low signal intensity 
on gradient-recalled echo (GRE) magnetic resonance imag-
ing (MRI).1,2 The location of CMBs varies according to the 
vascular pathophysiology: deep or infratentorial (nonlobar) 
CMBs are related to angiopathy with classical vascular risk 
factors, and lobar CMBs are related to cerebral amyloid an-
giopathy (CAA).1
Impaired kidney function is an independent risk factor for 
cardiovascular disease3 and stroke.4 Since the kidney and 
brain contain similar low-resistance microvascular structures 
and as end organs they both receive blood at a continuously 
high flow rate, they are vulnerable to blood pressure fluctua-
tions.5 It is therefore possible that impaired kidney function 
is associated with pathologies involving small vessels (end 
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Background and PurposezzCerebral microbleeds (CMBs) are associated with various patholo-
gies of the cerebral small vessels according to their distribution (i.e., cerebral amyloid angiopathy 
or hypertensive angiopathy). We investigated the association between CMB location and kidney 
function in acute ischemic stroke patients.
MethodszzWe enrolled 1669 consecutive patients with acute ischemic stroke who underwent 
gradient-recalled echo brain magnetic resonance imaging. Kidney function was determined using 
the estimated glomerular filtration rate (eGFR). CMBs were classified into strictly lobar, strictly 
nonlobar (i.e., only deep or infratentorial), and a combination of both lobar and nonlobar. Multi-
nomial logistic regression analyses were used to determine the factors associated with the exis-
tence of CMBs according to their location.
ResultszzThe patients were aged 66±12 years (mean±standard deviation), and 61.9% (1033/ 
1669) of them were male. CMBs were found in 27.0% (452/1669) of the patients. The stroke 
subtypes of small-artery occlusion and cardioembolism occurred more frequently in those with 
strictly nonlobar CMBs (10.8%) and strictly lobar CMBs (48.8%), respectively. The mean eGFR 
was lower in the strictly nonlobar CMBs group (72±28 mL/min/1.73 m2) and the both lobar and 
nonlobar CMBs group (72±25 mL/min/1.73 m2) than in the no-CMBs group (86±29 mL/
min/1.73 m2). Multivariate multinomial logistic regression revealed that eGFR <60 mL/min/1.73 m2 
was independently related to strictly nonlobar CMBs (odds ratio=2.63, p=0.001).
ConclusionszzImpaired kidney function is associated with strictly nonlobar CMBs. Our findings 
indicate that the distribution of CMBs should be considered when evaluating their relationships 
or prognoses. J Clin Neurol 2014;10(3):222-228
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arteries) in the brain.6 In support of this theory, it was found 
that impaired kidney function was a significant risk factor for 
CMBs in stroke.7-9 However, the relationship between location 
of CMBs and impaired kidney function is not well known.
Given that the mechanisms underlying the evolution of 
CMBs differ between nonlobar and lobar lesions, the associ-
ation between CMBs and impaired kidney function may dif-
fer according to their distribution. Therefore, we investigated 
the relationship between CMBs and impaired kidney func-
tion, and explored whether that association varies according 
to the location of CMBs in acute ischemic stroke patients.
Methods
Subjects
We enrolled 1902 consecutive patients between January 
2009 and December 2011 with acute cerebral infarction who 
were admitted within 7 days after symptom onset.10 All pa-
tients were evaluated based on the standard protocol of our 
hospital, which includes brain imaging studies [computed to-
mography (CT) and/or MRI], vascular imaging studies (digi-
tal subtraction angiography, MR angiography, or CT angiogra-
phy), chest radiography, 12-lead electrocardiography, routine 
blood tests, and continuous electrocardiographic monitoring 
during their stay in the stroke unit. Brain MRI was performed 
within 3 days after admission. The estimated glomerular fil-
tration rate (eGFR), which reflects kidney function, was cal-
culated using the Modification of Diet in Renal Disease for-
mula as11 eGFR=186.3×(serum creatinine-1.154)×(age-0.203)× 
(0.742 for women). Serum creatinine was measured at admis-
sion. If the eGFR was less than 90 mL/min/1.73 m2, serum 
creatinine was checked at least twice, and the value obtained 
closest to the time at which brain MRI was performed was 
used for this study. The stroke subtype was determined based 
on the Trial of Org 10172 in Acute Stroke Treatment classifi-
cation system.12 Patients were excluded from this study if 
they did not undergo brain MRI due to patient refusal, claus-
trophobia, or the presence of metallic material in the body 
(n=107). Patients with stroke due to other determined etiolo-
gy (rare causes, n=42), unavailable GRE images (n=45), lack 
of any blood laboratory results used for this study (n=16), 
poor image quality (n=15), or lack of vascular imaging stud-
ies (n=8) were also excluded. Ultimately, 1669 patients were 
included in this study, which was approved by the Severance 
Hospital Institutional Review Board of the Yonsei University 
Health System.
Risk factors and definition of variables
Hypertension was defined as being present when a patient had 
been taking blood-pressure-lowering agents or had a resting 
systolic/diastolic blood pressure of ≥140/≥90 mm Hg on re-
peated measurements. Diabetes mellitus was diagnosed when 
the patient had a fasting blood glucose level of ≥7.0 mmol/L 
or was being treated with oral glucose-lowering medications 
or insulin. Hyperlipidemia was diagnosed if the patient had 
total cholesterol and low-density lipoprotein levels of ≥6.2 
and ≥4.1 mmol/L, respectively, or if the patient had taken lip-
id-lowering medications after a diagnosis of hyperlipidemia. 
Patients were defined as smokers if they were current smokers 
or had stopped smoking within 1 year before the index stroke. 
Body mass index was calculated by dividing weight (in kilo-
grams) by height (in meters) squared. Coronary artery disease 
was defined as myocardial infarction, unstable angina, or an-
giographically confirmed coronary artery occlusive disease.
MRI protocol
All MRI examinations were performed using a 3.0-T MRI 
system (Achieva 3.0T, Philips Medical Systems, Best, The 
Netherlands; or MAGNETOM Trio 3.0T, Siemens, Germany). 
Brain MR images were obtained parallel to the orbitomeatal 
line using the following parameters, according to a previous 
study:13 fluid-attenuated inversion recovery (FLAIR) images-
repetition time (TR)/echo time (TE)=9000 ms/120 ms, field of 
view=230×230 mm2, pixel spacing=0.449 mm/0.449 mm, and 
slice thickness=5 mm; T2-weighted images-TR/TE=9000 
ms/100 ms, field of view=230×230 mm2, pixel spacing=0.240 
mm/0.240 mm, and slice thickness=5 mm; and GRE images-
TR/TE=600 ms/16 ms, field of view=250×250 mm2, pixel 
spacing=0.449 mm/0.449 mm, and slice thickness=5 mm. 
CMBs were defined as small, round, and hypointense lesions 
with a longest diameter in the range 3–10 mm. They were clas-
sified as either strictly lobar, strictly nonlobar (i.e., only in the 
deep or infratentorial areas), and a combination of both lobar 
and nonlobar on GRE images (Fig. 1). Strictly lobar CMBs 
were categorized into possible or probable CAA using previ-
ously reported methods.14,15 The presence of CMBs on GRE 
was independently reviewed by two neurologists (T.-J.S. and 
J.K.) who were blinded to the clinical information. The in-
terobserver agreement regarding the existence of CMBs was 
excellent (κ=0.92). Asymptomatic lacunar infarction was de-
fined as a hyperintense lesion of ≥3 mm and ≤15 mm on T2-
weighted images, and without a relevant history of symptoms 
or signs. We also investigated the severity of leukoaraiosis 
(LA) in our study patients. The extent of LA was determined 
based on FLAIR images of the periventricular white matter 
(PVWM) or deep white matter (DWM) using a previously es-
tablished method.16 LA in PVWM was classified as follows: 
grade 0, absent; grade 1, caps or pencil-thin lining; grade 2, 
smooth halo; and grade 3, irregular PVWM extending into 
DWM. LA in DWM was categorized as follows: grade 0, ab-
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sent; grade 1, punctate foci; grade 2, beginning confluence of 
foci; and grade 3, large confluent areas. For statistical analy-
ses, LA was defined as low-grade (Fazekas’ score of 0 or 1 in 
PVWM and DWM) and high-grade (Fazekas’ score of ≥2 in 
PVWM or DWM) white-matter change.13
Statistical analyses
Statistical analyses were performed using the Windows SPSS 
software package version 18.0 (SPSS Inc., Chicago, IL, USA). 
Continuous variables are reported as mean±standard devia-
tion values or as odds ratios and 95% confidence intervals. 
Categorical variables are presented as frequencies (i.e., n) and 
percentages. For comparison, patients were grouped accord-
ing to their eGFR values as ≥90, 60–90, and <60 mL/min/ 
1.73 m2. One-way analysis of variance with Bonferroni cor-
rected post-hoc analyses were used to compare continuous 
values according to CMB location. Categorical variables were 
compared by using the chi-square test or Fisher’s exact test. 
The association between number of CMBs and eGFR among 
the different CMB types was explored using Spearman cor-
relation analysis. Multinomial uni- and multivariate logistic 
regression analyses were conducted using the no-CMB group 
as the reference group for determining factors related to the 
existence of CMBs according to their location. Age, sex, and 
variables with p<0.1 in univariate analyses were entered into 
multivariate analyses. A two-tailed p value of <0.05 was con-
sidered significant.
Results
Comparisons according to CMB location
The demographic data of the study population are given in 
Table 1. The age was 66±12 years and 61.9% (1033/1669) of 
the study participants were male. CMBs were found in 27.0% 
of the subjects (452/1669; strictly lobar in 80 patients, strictly 
nonlobar in 278 patients, and a combination of both lobar 
and nonlobar in 94 patients). Of the 80 patients with strictly 
lobar CMBs, 15 (18.7%) had probable CAA and 65 (81.3%) 
had possible CAA. Patients with CMBs were older than those 
without CMBs. A history of hypertension, stroke, coronary 
artery disease, and antiplatelet medication, the presence of an 
asymptomatic lacunar infarction, and high-grade white-matter 
changes were more frequent in the three groups with CMBs 
than in the no-CMBs group (Table 1). Smoking was more 
frequent in the no-CMBs group than in the three groups with 
CMBs. The eGFR was lower in the strictly nonlobar CMBs 
group (72±28 mL/min/1.73 m2, p=0.001) and the both lobar 
and nonlobar CMBs group (72±25 mL/min/1.73 m2, p=0.001) 
than in the no-CMBs group (86±29 mL/min/1.73 m2). After 
categorizing the patients according to their eGFR values, pa-
tients with eGFR <60 mL/min/1.73 m2 were more common 
in the strictly nonlobar CMBs group and the both lobar and 
nonlobar CMBs group (p=0.001). The number of CMBs was 
inversely correlated with the presence of strictly nonlobar 
CMBs (r=-0.123, p=0.001) and both lobar and nonlobar CMBs 
(r=-0.182, p=0.001), but was not correlated with strictly lo-
bar CMBs (r=-0.041, p=0.142).
Factors associated with CMBs
In multivariate multinomial logistic regression, after adjusting 
age, sex, and p<0.1 in univariate analysis, a history of hyper-
tension and coronary artery disease and an eGFR of <60 mL/
min/1.73 m2 remained significant for strictly nonlobar CMBs 
(e.g., odds ratio=2.63, p=0.001 for an eGFR of <60 mL/
min/1.73 m2) (Table 2). When comparing the association be-
tween stroke subtypes and CMB location using multivariate 
logistic regression with the subtype of undetermined etiology 
due to a negative evaluation as a reference, cardioembolism 
A  B  C  
Fig. 1. Representative images demonstrating the classification of cerebral microbleeds into (A) strictly lobar CMBs, (B) strictly nonlobar 
CMBs, and (C) both lobar and nonlobar CMBs. CMBs: cerebral microbleeds.
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was more frequent in the strictly lobar CMBs group but less 
frequent in the strictly nonlobar CMBs group (Table 2). In ad-
dition, asymptomatic lacunar infarction and high-grade white-
matter changes were independently related with CMBs, re-
gardless of their location. We further analyzed the association 
between CMBs and impaired kidney function according to 
the presence or absence of diabetes mellitus, because a pre-
vious study found that impaired kidney function was associ-
ated with CMBs only among those without diabetes melli-
tus.7 The association between lower eGFR (<60 mL/min/1.73 
m2) and strictly nonlobar CMBs was significant in patients 
without (Supplementary Table 1) but not with (Supplementa-
ry Table 2) diabetes mellitus.
Discussion
Our findings demonstrate that the association between CMBs 
and impaired kidney function differs according to the location 
Table 1. Comparison of patient demographic characteristics and clinical data according to cerebral microbleed location
Total
(n=1669)
No CMBs
(n=1217)
Strictly lobar 
CMBs (n=80)
Strictly nonlobar 
CMBs (n=278)
Both lobar and 
nonlobar CMBs 
(n=94)
p
Demographic data
Sex, male 1033 (61.9) 760 (62.4) 46 (57.5) 169 (60.8) 58 (61.7) 0.811
Age, years 66±12 65±12 71±11* 69±11* 71±9* 0.001
Risk factors
Hypertension 1245 (74.6) 856 (70.3) 58 (72.5) 245 (88.1) 86 (91.5) 0.001
Diabetes mellitus 527 (31.6) 376 (30.9) 24 (30.0) 96 (34.5) 31 (33.0) 0.668
Hyperlipidemia 177 (10.6) 135 (11.1) 8 (10.0) 27 (9.7) 7 (7.4) 0.669
Previous stroke 323 (19.4) 202 (16.6) 19 (23.8) 70 (25.2) 32 (34.0) 0.001
Smoking 368 (22.0) 289 (23.7) 16 (20.0) 52 (18.7) 11 (11.7) 0.019
Coronary artery disease 391 (23.4) 259 (21.3) 25 (31.3) 87 (31.3) 20 (21.3) 0.001
Previous medications
Antiplatelet 641 (38.4) 429 (35.3) 39 (48.8) 133 (47.8) 40 (42.6) 0.001
Anticoagulant 98 (5.9) 73 (6.0) 6 (7.5) 13 (4.7) 6 (6.4) 0.757
Lipid-lowering 346 (20.7) 245 (20.1) 20 (25.0) 59 (21.2) 22 (23.4) 0.659
Stroke classification 0.001
Large-artery atherosclerosis 349 (20.9) 255 (21.0) 13 (16.3) 62 (22.3) 19 (20.2)
Small-artery occlusion 141 (8.4) 100 (8.2) 3 (3.8) 30 (10.8) 8 (8.5)
Cardioembolism 467 (28.0) 349 (28.7) 39 (48.8) 49 (17.6) 30 (31.9)
Undetermined etiology due to two 
  or more causes identified
354 (21.2) 258 (21.2) 17 (21.3) 59 (21.2) 20 (21.3)
Undetermined etiology due to 
  negative evaluation
358 (21.4) 255 (21.0) 8 (10.0) 78 (28.1) 17 (18.1)
Clinical data
Blood urea nitrogen, mmol/L 5.62±2.93 5.45±2.80 6.00±2.49 5.89±2.54 6.63±5.09* 0.001
Estimated GFR, mL/min/1.73 m2 0.001
≥90 603 (36.1) 487 (40.0) 25 (31.3) 70 (25.2) 21 (22.3)
60–90 759 (45.5) 559 (45.9) 40 (50.0) 118 (42.4) 42 (44.7)
<60 307 (18.4) 171 (14.1) 15 (18.8) 90 (32.4) 31 (33.0)
Total cholesterol, mmol/L 4.73±1.68 4.77±1.83 4.54±1.38 4.68±1.22 4.49±1.00 0.311
Low-density lipoprotein, mmol/L 2.77±1.11 2.82±1.17 2.63±1.05 2.70±0.95 2.59±0.85 0.080
High-density lipoprotein, mmol/L 1.10±0.28 1.10±0.28 1.08±0.30 1.09±0.30 1.07±0.28 0.613
Triglyceride, mmol/L 1.35±0.95 1.36±0.90 1.16±0.57 1.46±1.29† 1.14±0.48 0.009
Asymptomatic lacunar infarction 594 (35.6) 317 (26.0) 39 (48.8) 159 (57.2) 79 (84.0) 0.001
High-grade white-matter change 597 (35.8) 281 (23.1) 49 (61.3) 188 (67.6) 79 (84.0) 0.001
Data are presented as n (%) or mean±standard deviation values. 
*p<0.05 between the no-CMB and other lesion groups, †Both lobar and nonlobar CMBs, and strictly nonlobar CMBs, in Bonferroni 
post-hoc analyses.
CMBs: cerebral microbleeds, GFR: glomerular filtration rate.
Cerebral Microbleeds and Kidney Dysfunction
226  J Clin Neurol 2014;10(3):222-228
of the CMBs. Moreover, a low eGFR was correlated with 
strictly nonlobar CMBs but not with lobar CMBs, which sug-
gests that the associations between CMBs and impaired kid-
ney function noted in previous studies may have referred to 
strictly nonlobar CMBs rather than CMBs in other locations.
While CMBs have similar pathologies as putative markers 
of bleeding-prone angiopathy, they can develop via two dis-
tinct mechanisms: small-vessel-disease-related angiopathy 
due to classical vascular risk factors, or CAA. Preferential 
sites for CMBs that arise due to classical vascular risk factors 
and CAA are different because small-vessel pathologies de-
velop in deep brain areas where the perforating arteries pro-
vide the blood supply, whereas CAA develops mainly in the 
lobar area. CAA affects the arteries of the leptomeninges and 
cortex, and essentially does not involve the deep perforating 
arteries at the base of the brain and brain stem.17 In addition, 
a recent amyloid positron-emission tomography study showed 
that amyloid burden was correlated only with lobar CMBs.18 
Moreover, the risk factors for CAA are known to be associated 
with the apolipoprotein e-4 allele but not with kidney dys-
function.14 On the contrary, hypertensive vasculopathy most 
severely affects the perforating arteries of the brain.19 In this 
regard, the predilection site of CMBs may vary according to 
the pathophysiological mechanism of the angiopathy. The 
results of the present study support these previous findings.
Furthermore, impaired kidney function is associated with 
cerebral small-vessel disease, independent of other classical 
vascular risk factors.6,20 The association between impaired 
kidney function and small-vessel pathologies in strictly non-
lobar areas may be ascribed to the anatomical similarities be-
tween the vessels and the mechanism underlying dysfunction 
of the endothelial and smooth-muscle cells.21 In the kidney, 
small juxtamedullary afferent arterioles are subjected to high 
pressure and maintain a strong vascular tone.22 Since the per-
Table 2. Determinants for CMBs according to location
Characteristic
Multinomial multivariate logistic regression OR (95% CI)
Strictly lobar CMBs Strictly nonlobar CMBs Both lobar and nonlobar CMBs
Demographic data
Sex, male 1.11 (0.65–1.91) 1.21 (0.87–1.69) 1.47 (0.88–2.47)
Age, years 1.02 (0.99–1.04) 1.00 (0.98–1.01) 1.00 (0.97–1.02)
Risk factors
Hypertension 0.69 (0.39–1.23) 1.61 (1.05–2.46)* 1.94 (0.87–4.31)
Previous stroke 0.94 (0.51–1.72) 1.03 (0.71–1.49) 1.51 (0.88–2.59)
Smoking 1.34 (0.69–2.57) 0.92 (0.61–1.38) 0.61 (0.29–1.27)
Coronary artery disease 1.44 (0.85–2.44) 1.40 (1.00–1.96)* 0.86 (0.48–1.54)
Previous medications
Antiplatelet 1.16 (0.69–1.96) 1.08 (0.78–1.49) 0.63 (0.37–1.07)
Stroke classification
Undetermined etiology due to 
   negative evaluation
Reference Reference Reference
Large-artery atherosclerosis 0.61 (0.24–1.53) 1.19 (0.77–1.82) 0.83 (0.39–1.76)
Small-artery occlusion 0.97 (0.45–2.08) 0.71 (0.45–1.10) 0.74 (0.36–1.52)
Cardioembolism 2.19 (1.10–4.36)* 0.62 (0.39–0.98)* 1.18 (0.59–2.35)
Undetermined etiology due to two 
  or more causes identified
0.53 (0.14–1.96) 0.95 (0.54–1.66) 0.74 (0.28–1.94)
Clinical data
Blood urea nitrogen, mmol/L 1.01 (0.98–1.04) 0.98 (0.96–1.01) 1.02 (0.99–1.04)
Estimate GFR, mL/min/1.73 m2
≥90 Reference Reference Reference
60–90 1.13 (0.65–1.97) 1.19 (0.83–1.69) 1.95 (0.95–3.99)
<60 1.07 (0.49–2.32) 2.63 (1.67–4.13)* 1.19 (0.65–2.16)
Low-density lipoprotein, mmol/L 0.99 (0.99–1.00) 1.00 (0.99–1.00) 0.99 (0.99–1.00)
Triglyceride, mmol/L 0.99 (0.99–1.00) 1.00 (1.00–1.00) 0.99 (0.99–1.00)
Asymptomatic lacunar infarction 2.12 (1.27–3.52)* 2.12 (1.56–2.87)* 7.92 (4.32–14.51)*
High-grade white-matter change 3.65 (2.12–6.29)* 4.85 (3.49–6.75)* 8.58 (4.60–16.02)*
Overall reference value was the no-CMBs group.
*p<0.05.
CI: confidence interval, CMBs: cerebral microbleeds, GFR: glomerular filtration rate, OR: odds ratio.
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forating arteries in the brain share similar vascular compo-
nents to the kidney,22 the continuous delivery of high pressure 
(as in hypertension) to the deep perforating arteries in the 
brain may damage those arteries, resulting in the small-ves-
sel pathologies that produce CMBs. Impaired kidney func-
tion is also associated with endothelial dysfunctions such as 
reduced nitric oxide secretion,23 increased oxidative stress,24 
and up-regulation of cellular adhesion molecules,23 which are 
also involved in cerebral small-vessel pathologies.25 There-
fore, the anatomical and pathophysiological similarities of 
deep perforating-vessel damage in the kidney and brain may 
explain the association between impaired kidney function 
and the strictly nonlobar location of CMBs.
Another finding of our study was that CMBs were related 
to asymptomatic lacunar infarction and high-grade white-
matter changes, regardless of the location of CMBs, while 
impaired kidney function was associated with only strictly 
nonlobar CMBs. Although hypertensive vasculopathy is the 
main mechanism underlying small-vessel disease in the deep 
perforating artery territory, a chronic hypertensive state can 
also induce autoregulatory dysfunction of the pial superficial 
perforating arteries, which may result in damage to the 
smooth-muscle layer and microhemorrhage.26,27 Moreover, a 
previous study found that the volume of white-matter chang-
es and counts of asymptomatic lacunar infarctions were posi-
tively associated with the existence of CMBs, independent 
of their distribution.18 However, it is uncertain why the asso-
ciation between CMBs and their location in impaired kidney 
function differed from that in asymptomatic lacunar infarction 
or high-grade white-matter changes in our study population.
In our study, coronary artery disease was associated with 
strictly nonlobar CMBs. This finding could be attributed to 
the risk factors of coronary artery disease being similar to 
those of deep or infratentorial CMBs, such as hypertension, 
which is the main causative factor of nonlobar CMBs. Among 
the stroke subtypes, cardioembolism was positively associat-
ed with strictly lobar CMBs, but negatively associated with 
strictly nonlobar CMBs. The negative association between 
strictly nonlobar CMBs and cardioembolism may be due to 
the frequency of hypertension being lower in cardioembolism 
(71.1%) than in other stroke subtypes: large-artery athero-
sclerosis, 76.5%; small-artery occlusion, 83.0%; undetermined 
etiology due to negative evaluation, 73.2%; and undetermined 
etiology due to two or more causes identified, 75.1%. How-
ever, the reason why cardioembolism was associated with 
strictly lobar CMBs in our study population remains to be 
elucidated.
This study was subject to two main limitations. First, mark-
ers of kidney dysfunction other than eGRF, such as microal-
buminuria, were not evaluated.28 However, eGRF is a well-
known and valid marker of renal dysfunction.11 Second, our 
explanation regarding the mechanism underlying the differ-
ential association between kidney dysfunction and CMB dis-
tribution is based on the assumption that the former is related 
to vascular-risk-factor-related angiopathy and the latter is re-
lated to CAA; however, these diagnoses could not be patho-
logically confirmed in our study.
In conclusion, impaired kidney dysfunction was indepen-
dently associated with strictly nonlobar CMBs but not with 
lobar CMBs. Our findings also indicate that CMBs should be 
considered relative to their distribution when evaluating their 
relationships or prognoses.
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Supplementary Table 1. Determinants for CMBs according to location in patients without diabetes mellitus
Characteristics
Multinomial multivariate logistic regression OR (95% CI)
Strictly lobar CMBs Strictly non-lobar CMBs  Both lobar and non-lobar CMBs 
Demographic data
Sex, male 1.04 (0.55–1.96) 2.00 (1.02–3.93)* 1.38 (0.92–2.07)
Age, year 1.01 (0.98–1.04) 0.98 (0.94–1.01) 1.01 (0.99–1.03)
Risk factors
Hypertension 0.56 (0.29–1.08) 1.88 (0.73–4.89) 1.56 (0.95–2.57)
Previous stroke 1.23 (0.61–2.45) 1.44 (0.73–2.84) 0.91 (0.56–1.47)
Smoking 1.37 (0.61–3.05) 0.68 (0.29–1.59) 0.94 (0.57–1.54)
Coronary artery disease 1.21 (0.62–2.37) 1.43 (0.70–2.91) 1.44 (0.94–2.22)
Previous medications
Antiplatelet 1.09 (0.58–2.05) 0.59 (0.30–1.15) 1.00 (0.66–1.50)
Stroke classification
Undetermined etiology due to 
  negative evaluation
Reference Reference Reference
Large-artery atherosclerosis 0.60 (0.19–1.92) 1.39 (0.49–3.96) 1.42 (0.82–2.45)
Small-artery occlusion 1.07 (0.41–2.79) 1.76 (0.66–4.65) 0.75 (0.42–1.32)
Cardioembolism 2.60 (1.12–6.02)* 2.38 (0.92–6.13) 0.73 (0.41–1.28)
Undetermined etiology due to two or 
  more causes identified
0.26 (0.03–2.26) 0.75 (0.18–3.08) 1.14 (0.57–2.29)
Clinical data
Blood urea nitrogen, mmol/L 1.01 (0.98–1.04) 1.01 (0.94–1.04) 0.97 (0.94–1.01)
Estimate GFR, mL/min/1.73 m2
≥90 Reference Reference Reference
60–90 1.77 (0.73–4.30) 1.05 (0.51–2.19) 3.75 (2.11–6.67)*
<60 1.11 (0.58–2.13) 3.29 (1.33–8.15)* 1.34 (0.87–2.07)
Low density lipoprotein, mmol/L 1.00 (0.99–1.00) 1.00 (0.89–1.00) 1.00 (0.99–1.00)
Triglyceride, mmol/L 0.98 (0.99–1.00) 0.99 (0.99–1.00) 0.99 (0.99–1.00)
Asymptomatic lacunar infarction 2.02 (1.09–3.76)* 13.28 (5.66–31.17)* 2.14 (1.46–3.14)*
High grade white matter change 3.73 (1.92–7.24)* 11.74 (5.12–26.91)* 4.67 (3.11–7.02)*
Overall reference value was the no CMBs group.
*p<0.05.
CI: confidence interval, CMBs: cerebral microbleeds, GFR: glomerular filtration rate, OR: odds ratio.
Supplementary Table 2. Determinants for CMBs according to location in patients with diabetes mellitus
Characteristics
Multinomial multivariate logistic regression OR (95% CI)
Strictly lobar CMBs Strictly non-lobar CMBs  Both lobar and non-lobar CMBs 
Demographic data
Sex, male 1.44 (0.49–4.26) 0.99 (0.41–2.40) 0.89 (0.50–1.59)
Age, year 1.06 (1.00–1.13)* 1.02 (0.97–1.08) 0.98 (0.95–1.01)
Risk factors
Hypertension 1.21 (0.31–4.71) 1.27 (0.25–6.45) 2.00 (0.82–4.83)
Previous stroke 0.66 (0.19–2.28) 1.81 (0.67–4.92) 1.20 (0.65–2.22)
Smoking 1.82 (0.54–6.12) 0.23 (0.28–2.00) 0.96 (0.46–1.99)
Coronary artery disease 2.23 (0.87–5.71) 0.31 (0.09–1.05) 1.39 (0.79–2.44)
Previous medications
Antiplatelet 1.29 (0.48–3.49) 0.76 (0.30–1.93) 1.39 (0.79–2.44)
Stroke classification
Undetermined etiology due to 
  negative evaluation
Reference Reference Reference
Large-artery atherosclerosis 0.70 (0.15–3.33) 0.43 (0.13–1.42) 0.73 (0.35–1.54)
Small-artery occlusion 0.91 (0.24–3.41) 0.19 (0.04–0.83)* 0.63 (0.30–1.30)
Cardioembolism 1.93 (0.51–7.18) 0.37 (0.10–1.30) 0.41 (0.17–0.96)*
Undetermined etiology due to 
  two or more causes identified
1.06 (0.16–6.95) 0.73 (0.17–3.10) 0.57 (0.21–1.56)
Clinical data
Blood urea nitrogen, mmol/L 1.01 (0.97–1.06) 1.04 (1.01–1.08)* 1.01 (0.97–1.04)
Estimate GFR, mL/min/1.73 m2
≥90 Reference Reference Reference
60–90 1.08 (0.36–3.24) 1.41 (0.42–4.69) 0.93 (0.48–1.76)
<60 0.29 (0.05–1.52) 1.41 (0.36–5.45) 1.28 (0.58–2.81)
Low density lipoprotein, mmol/L 1.00 (0.99–1.00) 1.00 (0.99–1.00) 1.00 (0.99–1.00)
Triglyceride, mmol/L 0.98 (0.99–1.00) 0.99 (0.99–1.00) 0.99 (0.99–1.00)
Asymptomatic lacunar infarction 2.19 (0.86–5.57) 4.77 (1.85–12.33)* 1.97 (1.16–3.33)*
High grade white matter change 4.72 (1.60–13.88)* 7.89 (2.64–23.53)* 5.88 (3.22–10.72)*
Overall reference value was the no CMBs group.
*p<0.05
CI: confidence interval, CMBs: cerebral microbleeds, GFR: glomerular filtration rate, OR: odds ratio.
